FM November2020 Digital P

LabCor launches
IgG test to assess
effectiveness of
COVID-19 vaccines
LabCorp announced the launch of
a test that provides a quantitative
measurement of an individual’s SARS-
CoV-2 IgG antibodies.
Cov2Quant IgG test, which is
available only for use in clinical trials and
research, was developed to specifically
detect and quantify antibodies to SARS-
CoV-2, the virus that causes COVID-19.
Other COVID-19 antibody tests available
in the market are qualitative and detect
the presence of antibodies, but do not
provide information on the individual’s
antibody levels, LabCorp said.
The test is also currently being
utilized by the Centers for Disease
Control and Prevention (CDC) for
SARS-CoV-2 seroprevalence studies
to understand the level of antibodies
produced through natural exposure and
infection with the virus.
Eurofins’ home
COVID-19 nasal PCR
test receives EUA
An Emergency Use Authorization
(EUA) from the US FDA has been
granted to their at-home COVID-19 nasal
PCR test, Eurofins US Clinical Diagnostics
said.
The EUA authorized self-collection
kit gives consumers a minimally invasive,
convenient and quick option to test from
the comfort of their home.
Results are provided
via email within 24
hours of sample
receipt.
Eurofins’
infectious
disease centre
for excellence,
Viracor,
developed the test
based on its highly
sensitive, FDA EUAauthorized
SARS-
CoV-2 RT-PCR
assay.
ROCHE INTRODUCES
LABORATORY SARS-COV-2
ANTIGEN TEST
Roche will launch a high-volume
SARS-CoV-2 antigen test as an
aid in the diagnosis of SARS-
CoV-2 infection. The test is planned
to be made available at the end of
2020 for markets accepting the CE
mark. The Swiss drug major also
intends to file for Emergency Use
Authorisation (EUA) from the US FDA.
The Elecsys SARS-CoV-2 Antigen
test is a laboratory immunoassay for
the in vitro qualitative detection of
the nucleocapsid antigen of SARS-
CoV-2. The test is performed by
healthcare professionals and uses
nasopharyngeal or oropharyngeal
swab samples from patients with
signs and symptoms suggestive
of COVID-19 or people with either
known or suspected exposure to
SARS-CoV-2.
The Elecsys SARS-CoV-2 Antigen
immunoassay runs on all cobas e
immunochemistry analyzers. These
fully automated systems can provide
test results in 18 minutes for a single
test, with a throughput of up to 300
tests per hour from a single analyzer.
A laboratory-based automated
antigen assay allows for cost and
error reduction due to the removal
of manual handling as well as fast
turn-around times and high-test
throughput.
300
anitgen tests can be
done per hour in
a single analyser
22 / FUTURE
MEDICINE / November 2020